Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332 (25 February), doi:10.1136/bmj.332.7539.0-b
A combined strategy where quantitative fluorescent polymerase chain reaction (qf-PCR) is used in all pregnancies screened for trisomy 21 and full karyotyping is reserved only for those with increased fetal nuchal translucency thickness would be sensitive and cost effective. Lund and colleagues (p 452) analysed more than 17 000 chorionic villous samples (taken after measurement of fetal nuchal translucency thickness) by full karyotyping and by qf-PCR for chromosomes 13, 18, 21, X, and Y. They found that this strategy identified 99% of important chromosomal abnormalities and cost 60% less than karyotyping everyone.
|
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?